A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation

5Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Plasma biomarkers associated with respiratory failure (RF) following hematopoietic cell transplantation (HCT) have not been identified. Therefore, we aimed to validate early (7 and 14 days post-HCT) risk biomarkers for RF. Using tandem mass spectrometry, we compared plasma obtained at day 14 post-HCT from 15 patients with RF and 15 patients without RF. Six candidate proteins, from this discovery cohort or identified in the literature, were measured by enzyme-linked immunosorbent assay in day-7 and day-14 post-HCT samples from the training (n 5 213) and validation (n 5 119) cohorts. Cox proportional-hazard analyses with biomarkers dichotomized by Youden's index, as well as landmark analyses to determine the association between biomarkers and RF, were performed. Of the 6 markers, Stimulation-2 (ST2), WAP 4-disulfide core domain protein 2 (WFDC2), interleukin-6 (IL-6), and tumor necrosis factor receptor 1 (TNFR1), measured at day 14 post-HCT, had the most significant association with an increased risk for RF in the training cohort (ST2: hazard ratio [HR], 4.5, P =004; WFDC2: HR, 4.2, P =010; IL-6: HR, 6.9, P

Cite

CITATION STYLE

APA

Rowan, C. M., Smith, L., Sharron, M. P., Loftis, L., Kudchadkar, S., Duncan, C. N., … Paczesny, S. (2022). A biomarker panel for risk of early respiratory failure following hematopoietic cell transplantation. Blood Advances, 6(6), 1866–1878. https://doi.org/10.1182/bloodadvances.2021005770

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free